This is the first report of an integrated safety analysis for abrocitinib, using data pooled from one phase IIb study, four phase III studies, and one long-term extension study.

The most common adverse events were nausea, headache, and acne, which were all non-serious; most patients had events that were mild or moderate in severity.

Results suggest that abrocitinib, with proper patient and dose selection, has a manageable tolerability and long-term safety profile appropriate for long-term use in patients with moderate-to-severe atopic dermatitis.